ENTRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NTRK FUSION-POSITIVE SOLID TUMOURS: INTEGRATED ANALYSIS OF THREE PHASE 1–2 TRIALS

Sunday, July 26, 2020

Read the Story Here

Related Posts

Discover more posts like this.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Oct 25, 2024

Dr. Minal Barve

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Oct 14, 2024

Dr. Minal Barve

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider
See All Posts